Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 308 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Atorvastatin Clear all
Completed Phase 3 Interventional Results available

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

NCT01763866
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe, Atorvastatin, Rosuvastatin, Simvastatin
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
65
States / cities
Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Early Phase 1 Interventional

A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium

NCT02767362
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Atorvastatin
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Phase 4 Interventional Results available

Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)

NCT01600170
View directory record Official record
Conditions
HIV Dementia
Interventions
Atorvastatin (generic Lipitor), placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Phase 1 Interventional Results available

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

NCT01673178
View directory record Official record
Conditions
Diabetes Melliuts, Type 2
Interventions
Placebo, 25 mg PF-05231023, 50 mg PF-05231023, 100 mg PF-05231023, 150 mg PF-05231023
Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
17
States / cities
Anaheim, California • Chula Vista, California • Walnut Creek, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 17, 2026, 4:27 AM EDT
Terminated Phase 4 Interventional Results available

Quality of Life in Patients With Statin-Associated Myopathy

NCT00850460
View directory record Official record
Conditions
Statin Adverse Reaction
Interventions
Statins, Placebo
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
40 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Phase 2 Interventional

Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis

NCT00570752
View directory record Official record
Conditions
Vascular Diseases
Interventions
Placebo, BMS-582949, Atorvastatin, Statin
Other · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
17
States / cities
Chiefland, Florida • Jacksonville, Florida • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 17, 2026, 4:27 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Evaluation of Atorvastatin Treatment on Carotid Plaque.

NCT00343655
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Atorvastatin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)

NCT01617655
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
14
States / cities
Bell Gardens, California • Newport Beach, California • Northridge, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer

NCT01220973
View directory record Official record
Conditions
Prostate Cancer
Interventions
atorvastatin calcium, celecoxib, laboratory biomarker analysis
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Detroit, Michigan • Camden, New Jersey • Hamilton, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 17, 2026, 4:27 AM EDT
Terminated Phase 3 Interventional

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).

NCT00267280
View directory record Official record
Conditions
Hyperlipidemia, Dyslipidemia, Hypercholesterolemia
Interventions
torcetrapib/atorvastatin, simvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
51
States / cities
Birmingham, Alabama • Mesa, Arizona • Alhambra, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 17, 2026, 4:27 AM EDT
Not listed Phase 2 Interventional

Wake up Symptomatic Stroke - Benefit of Intravenous Clot Busters or Endovascular Intervention

NCT01455935
View directory record Official record
Conditions
Stroke
Interventions
Anti-platelets and statin, alteplase, intra arterial intervention
Drug · Procedure
Lead sponsor
Jacobs Neurological Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2012 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation

NCT01491958
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
Interventions
atorvastatin, Tacrolimus, methotrexate
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 17, 2026, 4:27 AM EDT
Terminated Phase 1 Interventional Results available

Clinical Utility of Endothelial Dysfunction in PAD

NCT00491751
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
atorvastatin, ascorbic acid, Placebo
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Not applicable Interventional

Pediatric Kidney Transplant Without Calcineurin Inhibitors

NCT00023231
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Daclizumab, Methylprednisolone/prednisone, Mycophenolate mofetil, Sirolimus, Bactrim, Ganciclovir, Lipitor
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease

NCT00296374
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Rosuvastatin, Atorvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
29
States / cities
Avondale, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

Hydroxychloroquine/Atorvastatin in the Treatment of Osteoarthritis (OA) of the Knee

NCT01645176
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Hydroxychloroquine/Atorvastatin
Drug
Lead sponsor
Stanford University
Other
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy

NCT05342974
View directory record Official record
Conditions
Abortion Early
Interventions
Atorvastatin, Misoprostol
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Results available

Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I

NCT01004406
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
intensive LDL-lowering therapy, standard statin monotherapy
Device · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
31 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Not applicable Interventional Results available

Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery

NCT00791648
View directory record Official record
Conditions
Acute Kidney Injury, Post-Operative Delirium, Icu Delirium, Acute Renal Failure, Delirium
Interventions
atorvastatin, placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CHOlesterol Lowering and Residual Risk in Type 2 Diabetes

NCT04369664
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Statin, PCSK9 inhibitor, Ezetimibe 10mg
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 89 Years
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants

NCT06293742
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ECC5004, Midazolam, Rosuvastatin, Digoxin, Atorvastatin
Drug
Lead sponsor
Eccogene
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Results available

Imaging of Coronary Plaques in Participants Treated With Evolocumab

NCT03570697
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
Evolocumab, Placebo, Statin therapy
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Elkhart, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 17, 2026, 4:27 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Improving Cardiovascular Health Risks in Adults With Epilepsy on a Modified Atkins Diet

NCT06369571
View directory record Official record
Conditions
Epilepsy, Dyslipidemia
Interventions
Atorvastatin 10mg, Modification of dietary fat composition
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

NCT01218204
View directory record Official record
Conditions
Dyslipidaemias, Dyslipidemias
Interventions
10mg atorvastatin, 80mg atorvastatin, GSK1292263 Placebo, 100mg GSK1292263, 300mg GSK1292263, 800mg GSK1292263, 10mg ezetimibe, Washout
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
21
States / cities
Anniston, Alabama • Chula Vista, California • Stockton, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 17, 2026, 4:27 AM EDT